Targeted protein degradation is becoming explored as a substitute system in cancer, whereby the all-natural protein degradation program is co-opted for therapeutic reasons. A short while ago formulated novel molecules referred to as proteolysis-concentrating on chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. Just one ligand https://www.directivepublications.org/journal-of-clinical-breast-cancer/